Background: To estimate the prevalence of adults and children with acute leukemia (AL) included in clinical trials and to determine factors associated with noninclusion. Results: A total of 1066 admissions with AL (85% of adults) were recorded, and 34 trials were open. In adults, the rate of inclusion in a trial was 25% [95% confidence interval (CI) 21% to 28%] for acute myeloid leukemia (AML) and 23% (95% CI 17% to 29%) for acute lymphoid leukemia (ALL). In children, the rate of inclusion was 58% (95% CI 41% to 73%) for AML and 64% (95% CI 55% to 72%) for ALL. The rate of inclusion varied across centers, with a significant increase when they were involved in clinical research. Patients included in trials differed significantly from those not included according to age, primary/secondary AL, leukemia type, results of cytogenetic analyses, and stage of disease.
introduction
It is acknowledged that patients may directly benefit from participating in a clinical trial, which can be explained by both access to innovative therapies [1] and more rigorous follow-up [2] . Some studies have shown that patients included in a clinical trial have increased survival [3] [4] [5] . Accessibility to clinical trials has also been considered as one way to reduce health care disparities. However, in oncology, only a small proportion (5%) of adult patients are included in clinical trials [6, 7] . This low rate of accrual leads to important consequences for the conduct of trials by increasing the duration of recruitment and also limits the extrapolation of results. Barriers to clinical trial enrollment have been largely studied among cancer patients [8, 9] and include primarily patient preference for a specific treatment, concerns about the randomization procedure or consent, and uncertainty about the efficacy of treatments as most often reported by patients. The barriers most often reported by physicians primarily involve an incompatibility of the protocol with normal practice, problems in complying with the protocol, and the consent procedure. For hematological malignancies, the prevalence of acute leukemia (AL) makes the number of patients available for research low. The rate of inclusion in clinical trials and the factors associated with noninclusion have not been extensively studied in this field. Only one retrospective monocenter study [10] has reported that 45% of 170 adults with de novo acute myeloid leukemia (AML) were included in a phase III trial.
Thus, the objectives of this prospective multicenter study were to estimate the proportion of both adults and children with AL included in clinical trials and to determine the factors associated with noninclusion.
materials and methods

study design
The study is a prospective observational analytic multicenter study.
setting
The study was conducted from October 2005 to June 2007. Of the 18 hematological departments managing AL in Paris area, 17 (14 adult specialized and 3 children specialized) participated in the study. They were located in 10 university teaching hospitals, 3 general hospitals, and 2 cancer centers; 12 (71%) had allogeneic stem cell transplantation activity at the time of the study. participants All consecutive patients with AL referred to one of the participating departments during the study period, and for whom a specific treatment decision regarding AL was made, were included in the study regardless of their age and type of AL. The diagnosis of AL was established by bone marrow morphology using the French-American-British (FAB) criteria. Patients could be included more than once in the case of new treatment decisions related to AL (i.e. for a relapse or for a refractory disease). Patients hospitalized for symptomatic treatment (e.g. febrile neutropenia requiring antibiotics) were excluded from the study, as were patients for whom the therapeutic decision was not made in one of the participating departments. Inclusion of all potentially eligible patients was checked in each department twice per month by the same independent monitor throughout the study period.
data collection
Data were collected prospectively on a standardized form by the referring physician of each department from patient charts, including laboratory reports on morphology and cytogenetic findings. Data collection was checked in each department twice monthly by the same independent monitor throughout the study period.
General patient characteristics. age, sex, and hospital department were recorded. Patients were classified according to the following age category since disease and management are very different: children <15 years old (in France, after 15 years, they are hospitalized in adult wards), adults £60 years old, and adults ‡61 years old.
Characteristics of AL. the type of AL was recorded according to the FAB classification. Bilineage AL and unclassified AL were listed separately. We noted whether the AL was secondary to myelodysplastic syndrome (AML-MDS), myeloproliferative syndrome, or a solid tumor. The results of cytogenetic analysis were recorded and classified as normal or exhibiting simple (less than or equal to two) or complex (greater than or equal to three) chromosomal aberrations [11] . 
43 (5) 135 (15) 16 (10) Autologous stem cell transplantation, n (%)
Palliative care/symptomatic treatment, n (%) 60 (7) 1 (1) Other, n (%) 21 (2) Table 2 .
characteristics of adult patients
Adult patients represented 85% of all observations (n = 902). The median age was 53 years (Q1: 35, Q3: 65). The 
characteristics of child patients
Children accounted for 15% of all observations (n = 164). The median age was 4.5 years (Q1: 3, Q3: 11). The proportion of secondary AL was low (2%). ALL represented 76% of child observations (with 54% ALL1). The ALL phenotype was B in 54%, pro B in 14%, and T in 6%. AML accounted for 24% of the observations, with non-APL AML in 21% of cases. There was no unclassified AL. Overall, first-line AL represented 84% of the observations, and the therapeutic decision primarily involved chemotherapy alone (89%).
availability of trials during the study period Table 3 shows the number of observations in the study according to age, type of AL, and stage of the disease in parallel with the corresponding number of trials available during the study period. The category comprising the highest number of patients was adults <60 years of age with first-line AML, accounting for 28% of all observations. The corresponding number of trials for this category was six (17% of all trials available). Conversely, some categories accounted for a low number of observations but a high number of trials available: for 5% and 0.5% of adults with refractory/relapsing ALL £60 years of age, respectively, there were nine (26%) and seven (20%) trials available, respectively.
inclusion of patients in clinical trials
adult patients. The proportion of observations for which a clinical trial corresponding to disease and stage was open in the department was 43% and 39% for AML and ALL, respectively. There was no trial open for unspecified AL. The rate of inclusion in a trial was, overall, 25% [95% confidence intervals (CI) 21% to 28%] for AML and 23% (95% CI 17% to 29%) for ALL. When a clinical trial was open in the department, the rate of inclusion in a trial reached 58% for AML and 61% for ALL. The rate of inclusion varied between departments from 11% up to 39%. As an example, Figure 1 displays the rate of inclusion according to the department in patients with first-line AML.
child patients. The proportion of observations for which a clinical trial corresponding to disease and stage was open in the department was 72% and 68% for AML and ALL, respectively. There were no trials open for unspecified AL. The rate of inclusion in a trial was, overall, 58% (95% CI 41% to 73%) for AML and 64% (95% CI 55% to 72%) for ALL. When a clinical trial was open in the department, the rate of inclusion in a trial was 79% for AML and 94% for ALL. The rate of inclusion varied between departments from 44% to 87%.
comparison of patient characteristics
There was a significant difference in age between patients included in trials and those who were not (P < 0.0001), with a higher proportion of children included (Table 4) . Patients not included in clinical trials presented significantly more secondary AL (P < 0.0001). For AML, patients not included in trials more frequently presented with MDS or unspecified AML than those included. In contrast, patients included in trials 
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more frequently presented with APL and a favorable karyotype than those who were not included. For ALL, patients included in trials more frequently presented with ALL 2 and pro B phenotypes and less often with bilineage ALL and the T phenotype than those who were not included in trials. Overall, patients included in trials were more often in first-line disease and less often in first relapse in comparison with those who were not included. The rate of inclusion varied significantly between hospitals (P < 0.0001). Patients included in trials were more often in departments in which physicians were the main investigators of the trials and for which there were a high number of open trials (92% versus 83%, P = 0.001). We restricted this latter analysis to adult departments because the number of open trials in all child departments was under the median (5, 4, and 5, respectively).
factors associated with noninclusion in a clinical trial adult patients. For AML, the proportion of patients for whom a trial was open was 60% ( Figure 2 ). When a trial was open, the main cause of noninclusion was ineligibility in 202 cases (48%) related to age outside limits (n = 101), comorbidities (n = 49), secondary AL (n = 25), and complications (n = 15). Patient refusal accounted for 24 (6%) noninclusions. In 11 cases (3%), the decision of noninclusion was made by the investigators. Finally, 11 patients were not included because they were waiting for bone marrow transplantation. For ALL, the proportion of patients for whom a trial was open was 51%. When a trial was open, the reasons for noninclusion also included ineligibility in 44 cases (44%), primarily related to age outside the limits (n = 29), comorbidities (n = 5), and characteristics of the AL (n = 5). Patients refused to enter into a trial in six cases (6%), and investigators decided to not include patients in five (5%) cases. Detailed reasons for patient refusal and investigator decisions not to include patients are shown in Table 5 . The main reasons for patient refusal included uncertainty concerning the results of treatments, presence of informed consent and randomization, and fear of toxicity. There was no trial open for patients with unclassified AL.
adult observations with AL:
658 first line 244 relapsing/refractory
(78%) with AML:
517 first line 184 relapsing/refractory
(22%) with ALL:
137 first line 58 relapsing/refractory Table 4 for detailed reasons).
original article Annals of Oncology child patients. The proportion of patients for whom a trial was open was 72% for AML and 68% for ALL (Figure 3 ). When a clinical trial was open, there was little exclusion due to ineligibility among children: four cases for AML and ALL. The rate of patient (or parental) refusal and decision of the investigator to not include the patient was also very low.
discussion
In this prospective multicenter survey, representative of the management of AL within a French area accounting for about 11 million people, we evaluated the clinical trials available, the rate of inclusion, and the reasons for noninclusion of patients suffering from AL. About one-quarter of adult patients with AML were included in a clinical trial, whereas 60% of children were included. In adults, the reasons for noninclusion were primarily ineligibility related to comorbidities, secondary AL, and age limit, in addition to patient refusal and investigator decision.
Our results indicate that in adults the rate of accrual in clinical trials is 25%. This rate is significantly greater than the rate usually reported in oncology, which is frequently <5%. In fact, in a study by Go et al. [15] , the rate of clinical trial accrual among new cancer patients at a community-based cancer center was 4% overall, with 15% of all patients refusing to participate in clinical trials. In our study, the overall rate of refusal was 3% in adults, and the reasons reported have been previously described in oncology [9] . Uncertainty about the treatment being the most effective, the randomization procedure and informed consent produced suspicion and confusion among the general population. A study has shown that better adapting information to the general population may decrease the refusal rate [16] . Simon et al. [17] suggested that improving patient knowledge and demand for clinical trials may significantly impact the participation rate. As already outlined by Comis et al. [18] , the primary problem with accrual is not the attitudes of patients, but rather the unavailability of an appropriate clinical trial for the disease, which we confirmed in this study. In 2003, Mengis et al. [10] argued for the need for trials designed for elderly patients or those with MDS together with a relatively unfavorable risk profile. In our study, several trials were available for elderly patients, with some being specifically designed for elderly patients. One phase II trial was specially designed for AML secondary to MDS. Thus, it seems that trials adequately cover the population of patients with AL. Nevertheless, not all trials are open for accrual in all centers, and physicians usually do not transfer patients to centers at which a clinical trial corresponding to their disease is open.
The management of AL is usually carried out in highly specialized departments and exclusively in public hospitals, which may explain the higher rate of inclusion compared with that in oncology. Our results also suggest that centers involved with clinical research are associated with a higher rate of inclusion in clinical trials. The higher rate of accrual among children compared with adults has already been reported in oncology. Tejeda et al. [7] estimated that >70% of children with cancer were included in national cooperative protocols as opposed to 4% of adults aged 20-49 years. In another study, the rate of accrual among children with cancer was >50% [19] . It is well established that children with AL have a higher rate of survival when they are treated in protocols [20, 21] . Our study confirms these results, showing that when a trial was open at the center for the disease, nearly all children were included compared with 60% of adults. It is not surprising that in adults, comorbidities and a history of previous cancer or MDS, which are still frequent exclusion criteria in trials, result in noninclusion. The higher rate of patient refusal and investigator decision not to include patients among adults compared with children is more unexpected.
The strengths of this study include the large population of patients recruited in all centers of one French administrative area during a relatively long time period, which enabled us to gather more representative results. Regular checking of inclusion and collection of data by an independent monitor enabled us to limit the omission of patients and the variability between centers.
In conclusion, the rate of inclusion in clinical trials of patients with AL is 25% for adults and 60% for children, which is relatively high compared with that described for patients with cancer. This difference may be explained by the higher number of trials available for AL, management in Table 4 for detailed reasons).
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